Toward the therapeutic editing of mutated RNA sequences.
If RNA editing could be rationally directed to mutated RNA sequences, genetic diseases caused by certain base substitutions could be treated. Here we use a synthetic complementary RNA oligonucleotide to direct the correction of a premature stop codon mutation in dystrophin RNA. The complementary RNA oligonucleotide was hybridized to a premature stop codon and the hybrid was treated with nuclear extracts containing the cellular enzyme double-stranded RNA adenosine deaminase. When the treated RNAs were translated in vitro, a dramatic increase in expression of a downstream luciferase coding region was observed. The cDNA sequence data are consistent with deamination of the adenosine in the UAG stop codon to inosine by double-stranded RNA adenosine deaminase. Injection of oligonucleotide-mRNA hybrids into Xenopus embryos also resulted in an increase in luciferase expression. These experiments demonstrate the principle of therapeutic RNA editing.
Woolf
T M
TM
Ribozyme Pharmaceuticals, Inc., Boulder, CO 80301, USA.
Chase
J M
JM
Stinchcomb
D T
DT
D000243:Adenosine Deaminase / Q000235:genetics; D000818:Animals; D001483:Base Sequence; D018388:Codon, Terminator; D016189:Dystrophin / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation; D012313:RNA / Q000235:genetics* / Q000627:therapeutic use; D017393:RNA Editing; D014981:Xenopus
D018388:Codon, Terminator; D016189:Dystrophin; D012313:RNA; D000243:Adenosine Deaminase